Overview
DefEYE develops decellularized placenta-derived biologics for eye care, including treatments for ocular surface diseases and use in eye surgeries. Its BIOVANCE line (BIOVANCE and BIOVANCE 3L Ocular) are amniotic membrane grafts, Interfyl is a flowable connective tissue matrix, and CentaFlex is a barrier membrane that supports healing. These products provide a placental-derived scaffold to protect and repair the eye’s surface. DefEYE differentiates itself through an exclusive sublicense with Celularity for its ophthalmic portfolio and Celularity as contract manufacturer, plus its focus on ophthalmic applications and partnerships with eye care professionals, aiming to expand regenerative options for ocular surface repair and surgical outcomes.
Work here?Claim your company
Simplify's take
What believers are saying
- Biovance 3L Ocular's October 2026 package insert shows active commercialization and regulatory upkeep.
- Celularity still lists DefEYE products in 2026 revenue, signaling established channel demand.
- The June 2026 secondary-manufacturer framework reduces single-supplier fragility during supply interruptions.
What critics are saying
- Celularity sued the relationship on May 7, 2026 for $1.34 million unpaid invoices.
- DefEYE lost Celularity's equity support after the June 3, 2026 stock return settlement.
- Celularity's March 2026 Biomaterials transfer to NexGel threatens DefEYE's supply leverage by 2027.
What makes DefEYE unique
- DefEYE owns exclusive ophthalmology rights to Celularity's placental biologics worldwide since October 22, 2025.
- Rob Sambursky brings repeat-founder credibility from RPS Diagnostics and Visus Therapeutics.
- BIOVANCE 3L Ocular targets ocular surface repair, pterygium surgery, and corneal reconstruction.
Help us improve and share your feedback! Did you find this helpful?